Pivotal readout
Elafibranor normalizes ALP in most PBC patients in phase 3 ELSPIRE
In ELSPIRE, which enrolled primary biliary cholangitis patients with only mildly raised alkaline phosphatase, 85.3% on elafibranor reached normal ALP by week 52 versus 23.3% on placebo, and the drug was well tolerated. The data were shown at this year's AASLD liver congress and are being filed with regulators.
- Drugelafibranor
- TargetPeroxisome proliferator‑activated receptor alpha
- TargetPeroxisome proliferator-activated receptor gamma
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.
